Brief: Cereno Scientific Announces Positive Topline Results Of Phase Iia Trial With Lead Candidate Cs1 In Pulmonary Arterial Hypertension
27/09/2024 19:42
Sept 27 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* CERENO SCIENTIFIC ANNOUNCES POSITIVE TOPLINE RESULTS OF
PHASE
IIA TRIAL WITH LEAD CANDIDATE CS1 IN PULMONARY ARTERIAL
HYPERTENSION
* CERENO SCIENTIFIC AB- CS1 - PHASE IIA SAFETY DATA -
PRIMARY
ENDPOINT OF SAFETY AND TOLERABILITY MET SUCCESSFULLY
Source text for Eikon: ID:nWkr35GSV0
Further company coverage: CRNOSb.ST
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global